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Abstract
Background: There is little consensus about how the influenza season should be defined in studies
that assess influenza-attributable risk. The objective of this study was to compare estimates of
influenza-associated risk in a defined clinical population using four different methods of defining the
influenza season.
Methods: Using the Studies of Left Ventricular Dysfunction (SOLVD) clinical database and national
influenza surveillance data from 1986–87 to 1990–91, four definitions were used to assess
influenza-associated risk: (a) three-week moving average of positive influenza isolates is at least 5%,
(b) three-week moving average of positive influenza isolates is at least 10%, (c) first and last positive
influenza isolate are identified, and (d) 5% of total number of positive isolates for the season are
obtained. The clinical data were from adults aged 21 to 80 with physician-diagnosed congestive
heart failure. All-cause hospitalization and all-cause mortality during the influenza seasons and non-
influenza seasons were compared using four definitions of the influenza season. Incidence analyses
and Cox regression were used to assess the effect of exposure to influenza season on all-cause
hospitalization and death using all four definitions.
Results: There was a higher risk of hospitalization associated with the influenza season, regardless
of how the start and stop of the influenza season was defined. The adjusted risk of hospitalization
was 8 to 10 percent higher during the influenza season compared to the non-influenza season when
the different definitions were used. However, exposure to influenza was not consistently
associated with higher risk of death when all definitions were used. When the 5% moving average
and first/last positive isolate definitions were used, exposure to influenza was associated with a
higher risk of death compared to non-exposure in this clinical population (adjusted hazard ratios
[HR], 1.16; 95% confidence interval [CI], 1.04 to 1.29 and adjusted HR, 1.19; 95% CI, 1.06 to 1.33,
respectively).
Conclusion: Estimates of influenza-attributable risk may vary depending on how influenza season
is defined and the outcome being assessed.
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Background
Complications associated with influenza infection have
been well described [1-5]. While the influenza season usu-
ally begins in November and ends in April in North Amer-
ica, the exact start and stop dates are not fixed. Since
periods of circulating influenza vary on both an annual
and regional basis, careful definitions of exposure are
needed when assessing the impact on outcomes such as
hospitalization and death. The Centers for Disease Con-
trol and Prevention (CDC) defines the start and stop of
the influenza season using a 5% moving average of posi-
tive influenza isolates obtained from weekly national sur-
veillance testing. However, many other definitions are
also used, including 5% of the total number of positive
isolates obtained for the whole season [6,7], the first and
last positive isolate identified [8-12], the "winter season"
[13,14], and when positive isolates exceed 10% of total
tested [4,15]. There is little consensus about exactly how
the influenza season should be defined in studies assess-
ing influenza-attributable risk.
To our knowledge, there have been no published studies
comparing the effect of using different differences on esti-
mates of complications of influenza. We previously con-
ducted an analysis to assess the effect of circulating
influenza season on hospitalization and death among
patients with congestive heart failure (CHF) [16]. We
report in this paper a comparison of four different meth-
ods to define the influenza season and assessed the effect
of these estimates on influenza-attributable hospitaliza-
tion and mortality using a database of patients with CHF.
Methods
To assess influenza-associated risks of hospitalization and
death (separately), we used the database of the Studies of
Left Ventricular Dysfunction (SOLVD) trials, which
included patients with physician-diagnosed CHF that
were followed prospectively for 5 years from 1986–1991
[17]. Data collected for the Studies of Left Ventricular Dys-
function (SOLVD) trials were used as the clinical data-
base. SOLVD consisted of two double-blind, placebo-
controlled randomized trials that examined the effect of
the angiotensin-converting-enzyme inhibitor enalapril on
morbidity and mortality in moderately severe CHF
patients (12, 13). Participants with CHF and left ventricu-
lar ejection fractions ≤ 35% who were already taking drugs
other than an angiotensin-converting-enzyme inhibitor
were eligible. Participants were ineligible if they were over
the age of 80 years or if they had any of the following:
hemodynamically serious valvular disease requiring sur-
gery, unstable angina, angina thought to be serious
enough to require revascularization procedures, myocar-
dial infarction in the previous month, severe pulmonary
disease, serum creatinine higher than 177 umol per litre,
or any other disease that might substantially shorten sur-
vival or impede participation in a long-term trial. Asymp-
tomatic CHF patients, defined as those with no clinical
symptoms of CHF, were enrolled in the SOLVD Preven-
tion trial, while symptomatic CHF patients were enrolled
in the SOLVD Treatment trial. Participants were followed
prospectively from 1986 to 1991. During this period,
39,924 patients with ejection fractions ≤ 35% were identi-
fied. Of these 6.4% or 2,569 were enrolled in the treat-
ment trial and 7.4% or 4,228 were enrolled in the
prevention trial. The reasons for exclusion included the
following: use of an angiotensin-converting-enzyme
inhibitor (28%), cardiovascular problems (12%), con-
traindications to use of an angiotensin-converting-
enzyme inhibitor (11%), lack of consent (11%), adminis-
trative reasons (21%), cancer or other life-threatening dis-
ease (12%), other reasons (5%). There were 24 study sites
of which 21 were located throughout the continental US,
two in Canada, and one in Belgium (12, 13). Each was
comprised of one to eight hospitals. Only participants
from the 21 US sites were included in our analysis, since
weekly influenza isolate data were available. A small
number (<1%) of the participants were excluded because
the exact date of their first hospitalization post-randomi-
zation could not be determined, leaving 5,448 people in
the study population.
National influenza surveillance data from 1986–1987 to
1990–1991 were obtained from the Influenza Branch of
the Centers for Disease Control and Prevention. The
weekly number of isolates submitted for testing each year
and the weekly number of positive tests obtained each
year (by virus type and subtype) were used identify the
start and stop of the influenza season using four methods.
Isolate data and SOLVD study sites were classified into
four regions: Central, Northeast, West, and South.
The following four methods were used to define the start
and stop of the influenza seasons: 5% moving average,
10% moving average, first and last isolate, and 5% total
season isolates. The 5% moving average refers to the first
and last week during which the three-week moving aver-
age of influenza isolates submitted for testing was at least
5 percent positive. The 10% moving average refers to the
first and last week in which the three-week moving aver-
age of influenza isolates submitted for testing was at least
10 percent positive. The first/last isolate refers to the weeks
in which the first and last positive influenza isolate for
that season was identified. The 5% total season refers to the
weeks during which the number of positive influenza iso-
lates obtained was at least 5% of the total number of pos-
itive influenza isolates obtained for the entire season.
Hospitalization and mortality rates during the influenza
seasons and non-influenza seasons were compared for
each different definition of the influenza season. AllBMC Public Health 2008, 8:59 http://www.biomedcentral.com/1471-2458/8/59
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patient-days at risk during the influenza season and non-
influenza seasons were calculated based on date of rand-
omization, dates of the beginning and end of each influ-
enza season, and the date of hospitalization, death or last
SOLVD visit. Incidence rates of first-time hospitalization
were determined by dividing the number of events during
a given time period (influenza or non-influenza season)
by the total days at risk for eligible individuals during the
same period. Days at risk were calculated from the date of
enrolment into the study until the date of the first hospi-
talization or, if no hospitalization occurred, until the date
of the final follow up visit. We calculated the rate ratio
(relative risk) and 95% confidence intervals (CI) for hos-
pitalization and mortality during the combined influenza
seasons when compared to combined non-influenza sea-
sons.
Cox regression was used to assess the effect of exposure to
flu season on all-cause hospitalization and death for each
different definition of the influenza season and adjusted
hazard ratios were compared. Adjustment for sex, age,
enalapril use, severity of congestive heart failure (based on
the New York Heart Classification) [18] and co-morbidi-
ties (using the Charlson Index) [19] was performed. The
influenza season for each participant was defined as a
time-dependent variable based on his/her randomization
date and follow-up time, and on the dates of the influenza
season of his/her region during each study year. In our
previous analysis, daily temperature was forced into the
multivariable model [16]. However, since this variable
was not significant, we did not include it in the present set
of analyses.
To compare the effects of the hazard ratio and time of
exposure to influenza season of the difference definitions
of the influenza season, we calculated the proportion of
hospitalizations and deaths attributable to influenza
(hazard ratio – 1/hazard ratio) and multiplied this by the
number of events (hospitalizations or deaths) within the
influenza season however defined. Using patient-days as
the denominator and the attributable events as the
numerator, we calculated the annualized rate of attributa-
ble hospitalizations and deaths.
Results
Risk of Hospitalization during the Influenza Season
Hospitalization rates during the influenza and non-influ-
enza season for all-years combined when the four meth-
ods were used are shown in Table 1. The number of
hospitalizations was highest when the influenza season
was represented by a larger period of calendar time. When
more restricted definitions were used, fewer hospitaliza-
tions were categorized as influenza-related events.
The calculated relative risk (unadjusted) showed that
overall hospitalization rates during the influenza season
were higher than hospitalization rates during the non-
influenza season for all methods (5% moving average: RR,
1.08; 95% CI, 1.01 to 1.16; 10% moving average: RR,
1.07; 95% CI, 0.99 to 1.15; first/last: RR, 1.09; 95% CI,
1.01 to 1.13; 5% total: RR, 1.04; 95% CI, 0.93 to 1.13).
However, only the 5% moving average and first/last iso-
late definitions showed a significant difference between
rates during the influenza season and non-influenza sea-
son. Hospitalization rates during the influenza season
were relatively similar when different definitions were
Table 1: Comparing hospitalization rates during the influenza season and non-influenza season using different methods of defining the 
influenza season, 1986–87 to 1990–91.
Influenza Season* Non-Influenza Season* Relative Risk (95% Confidence Interval)
5% Moving Average
Rate 11.39 10.52 1.08 (1.01–1.16)
Events, No. 1204 2177
Patient-days, No. 1057293 2069683
10% Moving Average
Rate 11.34 10.63 1.07 (0.99–1.15)
Events, No. 901 2480
Patient-days, No. 794239 2332737
First/Last
Rate 11.26 10.35 1.09 (1.01–1.16)
Events, No. 1777 1604
Patient-days, No. 1577740 1549236
5% Total Season
Rate 11.18 10.72 1.04 (0.96–1.13)
Events, No. 687 2694
Patient-days, No. 614407 2512569
* Rates are per 10,000 patient-daysBMC Public Health 2008, 8:59 http://www.biomedcentral.com/1471-2458/8/59
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used. The highest and lowest hospitalization rates during
the influenza season were obtained when the 5% moving
average and 5% total season definitions were used, respec-
tively.
The unadjusted hazard ratio associated with exposure to
influenza was determined by constructing Cox models
with only the influenza season variable (Table 2). For the
hospitalization model, the unadjusted hazard ratios asso-
ciated with influenza using 5% moving average, 10%
moving average, first/last isolate and 5% total season iso-
lates were 1.09 (95% CI, 1.02 to 1.17), 1.04 (95% CI, 0.97
to 1.11), 1.07 (95% CI, 0.99 to 1.14), and 1.07 (95% CI,
0.99 to 1.15), respectively (Table 2). The hazard ratios for
hospitalization associated with influenza remained rela-
tively constant when adjusted for other variables for all
definitions except for the 10% moving average, which
increased by five percent (Table 2). However, when the
hazard ratio was adjusted for other variables using the
10% moving average, influenza season was found to be
significant (as it was for other definitions). The rate of
attributable excess hospitalizations was variable depend-
ing on the definition use. Notably, the annualized rate of
hospitalizations was highly variable, ranging from 5.95
(5% total season) to 15.41 (first/last) hospitalizations per
1,000 patient-years depending on the definition used.
Risk of Death during the Influenza Season
Death rates for all years combined during influenza and
non-influenza seasons are shown in Table 3. Using the
four definitions, relative risk of death were as follows: 5%
moving average: RR, 1.09; 95% CI, 0.97 to 1.21; 10%
moving average: RR, 1.08; 95% CI, 0.95 to 1.21; first/last:
RR, 1.15; 95% CI, 1.02 to 1.27; 5% total: RR, 1.06; 95%
CI, 0.92 to 1.20. The highest and lowest death rates during
the influenza season were obtained when the first/last iso-
late and 5% moving average definitions were used, respec-
tively.
For the death model, the unadjusted hazard ratios associ-
ated with the influenza season using 5% moving average,
10% moving average, first/last isolate and 5% total season
isolates were: 1.09 (95% CI, 0.97 to 1.21), 1.08 (95% CI,
0.95 to 1.21), 1.15 (95% CI, 1.02 to 1.27), and 1.06 (95%
CI, 0.92 to 1.20), respectively (Table 4). The unadjusted
hazard ratios were similar to the unadjusted relative risk
obtained in the incidence rate analysis. Depending on
which definition was used, the hazard ratios for death
associated with the influenza season increased by five to
eight percent when adjusted for other variables (Table 4).
As seen with hospitalization, the rate of attributable excess
deaths was variable depending on the definition use.
There was striking variation in the annualized rate of
deaths attributable to influenza, ranging from 0.71 (5%
total season) to 8.10 (first/last isolate) deaths per 1,000
patients per year depending on the definition used.
Discussion
Overall, the hospitalization models were very similar and
the covariates had similar direction and size of effect.
Most notably, exposure to influenza was statistically sig-
nificant in all adjusted models, suggesting that circulating
influenza had an effect on hospitalization during the
entire circulating period as well as during the peak circu-
lating periods. The overall risk of hospitalization during
the influenza season varied between 8–10% for the four
methods. In all adjusted models, irrespective of which
influenza definition was used, the direction and magni-
tude of effects for the individual-level covariates (being
symptomatic for CHF, being older, not being on enalapril,
having a higher Charlson score, having a higher NYHA
class and having a lower ejection fraction) also remained
constant (data not shown). Estimated risk of hospitaliza-
tion during the influenza season dropped by one or two
percent when definitions other than the standard CDC
definition were used (i.e. 5% moving average) (Table 2).
Only small differences between unadjusted relative risk
and unadjusted hazard ratios occurred when the various
definitions to determine influenza-associated risk were
compared. The relative risk comparing the overall event
rates during the influenza season with the non-influenza
season were cruder estimates of influenza – associated risk
when compared to the hazard ratio estimates, which cal-
Table 2: Comparison of estimated risk of hospitalization associated with influenza season using different methods of defining the 
influenza season.
Flu Season Definition Unadjusted Hazard Ratio 
(95% CI)
Adjusted Hazard Ratio* 
(95% CI)
Number of hospitalizations 
attributable to influenza
Rate of Attributable Excess 
hospitalizations** (95%CI)
5% Moving Average 1.09 (1.02–1.17) 1.10 (1.04–1.18) 109 12.72 (10.35 to 15.47)
10% Moving Average 1.04 (0.97–1.11) 1.09 (1.02–1.17) 74 8.64 (6.74 to 10.58)
First/Last Isolate 1.07 (0.995–1.14) 1.08 (1.01–1.16) 132 15.41 (12.54 to 18.74)
5% Total Season Isolates 1.07 (0.989–1.15) 1.08 (1.00–1.17) 51 5.95 (4.43 to 7.82)
CI = confidence interval;
* adjusted for trial, age group, NYHA class, co-morbidity index score, enalapril therapy, ejection fraction, and study site.
**Rates are per 1,000 patient-yearsBMC Public Health 2008, 8:59 http://www.biomedcentral.com/1471-2458/8/59
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culated the absolute baseline hazard for hospitalization
over time. The unadjusted and adjusted hazard ratios were
similar. The effect size of influenza season remained con-
stant despite the higher effect sizes of the individual-level
covariates.
For the death model, the adjusted hazard ratios varied
considerably between the four methods (Table 4). Unex-
pectedly, the model using a 10% moving average did not
show the greatest effect on death. This would have been
expected since it represented the strictest definition of the
influenza season. However, influenza season showed a
significant effect on death only when the 5% moving aver-
age and first/last isolate definitions were used. Addition-
ally, the greatest effect size (adjusted HR, 1.19) was seen
when the first/last definition was used. One possible
explanation for this is that by increasing the length of the
influenza season, the 5% moving average and the first/last
isolate definitions limited the reference period to summer
months when there is less likely to have circulating respi-
ratory viruses.
Only the adjusted multivariable models using the 5%
moving average and first/last isolate definitions showed
an association between circulating influenza and hospi-
talizations as well as an association between influenza
and death. The first/last isolate definition was the broad-
est definition. The annualized influenza attributable rates
of hospitalization and death were quite variable depend-
ing on the definition used (Tables 2 and 4). It could be
that while all influenza-attributable events were identi-
fied, hospitalizations and deaths not related to influenza
(but due to co-circulating viruses such as respiratory syn-
citial virus) may have been incorrectly attributed to influ-
enza. The 5% total season measure will likely identify
most influenza attributable cases, but since the number of
tests done each week and each season were not consid-
ered, this method may not be reliable during seasons in
which influenza testing is low. The fact that the estimates
Table 3: Comparing death rates during the influenza season and non-influenza season using different methods of defining the influenza 
season, 1986–87 to 1990–91.
Influenza Season* Non-Influenza Season* Relative Risk (95% Confidence Interval)
5% Moving Average
Rate 27.10 24.87 1.09 (0.97–1.21)
Events, No. 475 841
Patient-days, No. 1752471 3382155
10% Moving Average
Rate 27.13 25.11 1.08 (0.95–1.21)
Events, No. 358 958
Patient-days, No. 1319485 3815141
First/Last
Rate 27.34 23.86 1.15 (1.02–1.27)
Events, No. 713 603
Patient-days, No. 2607851 2526805
5% Total Season
Rate 26.79 25.35 1.06 (0.92–1.20)
Events, No. 271 1045
Patient-days, No. 1011662 4122964
* Rates are per 100,000 patient-days
Table 4: Comparison of estimated risk of death associated with influenza season using different methods of defining the influenza 
season.
Flu Season Definition Unadjusted Hazard Ratio 
(95% CI)
Adjusted Hazard Ratio* 
(95% CI)
Number of deaths 
attributable to influenza
Rate of Attributable Excess 
Deaths** (95%CI)
5% Moving Average 1.10 (0.98–1.22) 1.16 (1.04–1.29) 66 4.69 (3.61 to 5.96)
10% Moving Average 1.03 (0.92–1.15) 1.08 (0.97–1.21) 27 1.92 (1.27 to 2.79)
First/Last Isolate 1.11 (0.995–1.24) 1.19 (1.06–1.33) 114 8.10(6.59 to 9.85)
5% Total Season Isolates 0.997 (0.881–1.13) 1.04 (0.92–1.18) 10 0.71 (0.34 to 1.31)
CI = confidence interval;
* adjusted for trial, age group, NYHA class, co-morbidity index score, enalapril therapy, ejection fraction, and study site.
**Rates are per 1,000 patient-yearsBMC Public Health 2008, 8:59 http://www.biomedcentral.com/1471-2458/8/59
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of risk were consistent when using hospitalization but not
mortality raises the importance of the effect of the out-
come.
Our analysis has several limitations. Influenza vaccina-
tion has been shown to be effective at reducing morbidity
and mortality associated with influenza infection [19]. No
reliable information was available for each study partici-
pant on influenza vaccination. However, in 1998, only
43% of people with chronic pulmonary and cardiac con-
ditions were vaccinated against influenza and it is likely
that vaccination coverage was even lower during the study
period used here [20]. Thus, vaccination status probably
did not affect the reported rates and the proposed models
here.
As well, there was no individual-level data on exposure to
and infection with influenza. Our assumption is that
study patients living in a particular geographic region
were exposed to the virus during the circulating period
and that this exposure increased the probability of hospi-
talization or death.
Influenza A(H3N2) is associated with more serious mor-
bidity and mortality than influenza A(H1N1) and influ-
enza B [21]. In our analysis, the cumulative risk was
determined by assuming that the risks of hospitalization
and death was similar across years, but the predominant
influenza type differed by study year. During our study
period, years 2 and 4 were predominantly A(H3N2), year
1 was mostly A(H1N1) and years 3 and 5 were mostly
influenza B (Table 5). Furthermore, the predominant
influenza subtype may not be the same in all regions, thus
potentially affecting risk geographically. In our case, how-
ever, the predominant type was the same in all regions for
most years.
Attributing a particular influenza type to each participant
was not possible since there was no individual level data
available that could identify the exact influenza subtype
that each person was exposed to and for how long.
It must also be acknowledged that hospitalizations for
heart-related causes are higher during winter months
compared to summer months [22-26]. The winter season
and the influenza season usually fall during similar calen-
dar periods, suggesting that there may be confounding
due to more hospitalizations occurring during the winter.
However, since it was not controlled for in these popula-
tion-based studies, there was no way to determine
whether the effect reported was due to respiratory viruses
versus other reasons, such as lower immune response dur-
Table 5: Start and stop weeks of influenza season using various definitions from 1986–87 to 1990–91 influenza seasons by United States 
regions. Patients in the study were enrolled from a study site within one of the four regions.
Region Year First last isolate 10% moving average 5% moving average 5% all isolates
Start Stop Start Stop Start Stop Start Stop
Central 86–87 49 17 51 5 50 9 51 7
N o r t h e a s t 4 41 15 0 5 4 9 6 5 0 4
S o u t h 4 51 65 3 9 5 11 0 1 6
W e s t 4 585 154 865 25
C e n t r a l 8 7 – 8 8 4 6 2 241 832 141 3
N o r t h e a s t 12 271 462 381 3
S o u t h 5 0 2 541 431 441 3
W e s t 5 2 2 0 23192 1 1
C e n t r a l 8 8 – 8 9 4 7 1 921 211 531 0
N o r t h e a s t 4 7 1 821 811 841 0
S o u t h 5 01 95 11 55 12 0 3 1 1
W e s t 5 1 1 781 041 331 3
Central 89–90 47 17 51 11 50 12 52 9
N o r t h e a s t 4 82 1 1 1 15 21 2 2 1 0
S o u t h 4 81 25 01 25 01 35 1 8
West 46 11 3 6 52 9 51 8
C e n t r a l 9 0 – 9 1 4 8 1 951 431 441 3
N o r t h e a s t 4 52 2 3 1 05 01 7 3 8
S o u t h 4 01 9 1 1 65 11 9 3 8
West 52 21 5 9 5 12BMC Public Health 2008, 8:59 http://www.biomedcentral.com/1471-2458/8/59
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ing colder temperatures, less frequent physical activity,
and/or depression.
Conclusion
How influenza season is defined can have an important
influence on estimates of association when evaluating
influenza-attributable risk. The definitions can have a dif-
ferential impact depending on the outcome being consid-
ered.
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